Add to ORKGSeven Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients in first complete remission received maintenance therapy with imatinib alone. Two-year progression-free survival was 75%. Quantitative polymerase-chain-reaction (qPCR) monitoring of BCR-ABL showed that: (i) persisting molecular complete response (CR) was associated with long-lasting CR; (ii) molecular relapse did not invariably mean hematologic relapse; (iii) only the wide and rapid increment of BCR-ABL values was predictive of leukemia relapse
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
The Philadelphia chromosome positive arm of the UKALLXII/ECOG2993 study for adult acute lymphoblasti...
Background Relapse happens frequently after allogeneic hematopoietic cell transplantation (allo-HCT)...
Background: The advent of imatinib has considerably changed the treatment of chronic myeloid leukemi...
Imatinib induces a high complete cytogenetic response (CCR) rate in relapsed chronic myelogenous leu...
Background: Maintenance therapy with imatinib during the post-transplant period has been used for pa...
none10Using quantitative reverse-transcription polymerase chain reaction we investigated the signifi...
Aim: To compare a less intensive regimen based on high-dose imatinib (IM) to an intensive IM/HyperCV...
Background: Tyrosine Kinase Inhibitors (TKI) have been shown to be very effective for the treatment ...
© 2020, The Author(s), under exclusive licence to Springer Nature Limited. In chronic-phase chronic ...
AimThe aim of this works is the presentation of two cases of relapsed Ph positive acute lymphoblasti...
BCR-ABL fusion gene t(9;22)(q34;q11) occurs in only 3% of pediatric acute lymphoblastic leukemia (AL...
BACKGROUND: The use of imatinib combined with chemotherapy has demonstrated improved outcome in adul...
BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels ...
Imatinib mesylate, an inhibitor of the Bcr-Abl tyrosine kinase, has modest activity in refractory/re...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
The Philadelphia chromosome positive arm of the UKALLXII/ECOG2993 study for adult acute lymphoblasti...
Background Relapse happens frequently after allogeneic hematopoietic cell transplantation (allo-HCT)...
Background: The advent of imatinib has considerably changed the treatment of chronic myeloid leukemi...
Imatinib induces a high complete cytogenetic response (CCR) rate in relapsed chronic myelogenous leu...
Background: Maintenance therapy with imatinib during the post-transplant period has been used for pa...
none10Using quantitative reverse-transcription polymerase chain reaction we investigated the signifi...
Aim: To compare a less intensive regimen based on high-dose imatinib (IM) to an intensive IM/HyperCV...
Background: Tyrosine Kinase Inhibitors (TKI) have been shown to be very effective for the treatment ...
© 2020, The Author(s), under exclusive licence to Springer Nature Limited. In chronic-phase chronic ...
AimThe aim of this works is the presentation of two cases of relapsed Ph positive acute lymphoblasti...
BCR-ABL fusion gene t(9;22)(q34;q11) occurs in only 3% of pediatric acute lymphoblastic leukemia (AL...
BACKGROUND: The use of imatinib combined with chemotherapy has demonstrated improved outcome in adul...
BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels ...
Imatinib mesylate, an inhibitor of the Bcr-Abl tyrosine kinase, has modest activity in refractory/re...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
The Philadelphia chromosome positive arm of the UKALLXII/ECOG2993 study for adult acute lymphoblasti...
Background Relapse happens frequently after allogeneic hematopoietic cell transplantation (allo-HCT)...